Full coverage: Start-ups

Six years on from founding CitySwift, Brian O’Rourke and Alan Farrelly explain how they developed AI to optimise bus fleets, sold it to the UK’s major operators and are now going international – having raised funds from A-list investors including Ryanair’s founding family along the way.

On the back of its success backing companies like LetsGetChecked and Flipdish, Alan Merriman's Elkstone has convinced the authorities of applying EIIS tax advantages to a multi-company investment fund targeting early-stage companies in Ireland.

John Ryan's life has taken some turns. He left corporate finance to join the army; now he's the founder and CEO of Gigable, a marketplace that connects independent workers with businesses. He talks about his journey, international expansion and the future of the gig economy.

Adele Cooper could have stayed at the top of Silicon Valley. Instead, she explains why she decided to join the fast-growing gifting platform &Open and shares key advice to drive B2B sales.

The co-founders of Sisu believe the aesthetic clinic group will become a multi-billion dollar public company. Pat Phelan and Brian and James Cotter talk about US expansion, why it has reignited plans to enter the UK, and the economics of "face-as-a-service".

The Irish-owned single parent online community Frolo has raised seed capital in London and Pinergy saw revenue and gross profit grow, reducing pre-tax losses – but among other businesses filing this week, Bono's sustainable fashion brand and the former PolarLake had less positive news.

HealthBeacon helps patients self-administer medications. Now investors must weigh-up its tenfold growth predications, as it seeks to raise €25 million from a stock market flotation.

Irish biotech firm Avectas hopes to revolutionise cancer treatment. This is the story of the company: How it was formed, how it has raised $40m from leading Irish investors to help its mission, and what it plans to do next.

MicroSynbiotiX is merging with Sundew, a like-minded aquaculture technology company aiming to protect farmed fish from disease with minimal environmental impact. A Dublin-based VC is funding the enlarged business.

As an early-stage biotechnology company, Nuritas lives and dies by its investors' backing. A big new funding round that includes big names from the US, Europe and the UK is a vote of confidence in the company's prospects.